newsfilter
← Latest News
GlobeNewswire·

OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

OPRX
  • OptimizeRx reported Q3 2026 revenue of $21.6 million, a 17% decrease from $26.1 million in Q3 2025.
  • The company recorded GAAP net income of $1.2 million ($0.06 per share) & adjusted EBITDA of $6.3 million for the quarter.
  • Non-GAAP net income for Q3 2026 totaled $3.8 million ($0.20 per diluted share), up from $3.1 million in the prior-year period.
  • Fiscal 2026 revenue guidance was updated to a range of $87 million to $93 million, while adjusted EBITDA guidance remains unchanged at $21 million to $25 million.
  • The company repaid $9.3 million in debt principal since June 30, 2026, reducing outstanding debt to $10.4 million.
  • Operating cash flow for the nine months ended September 30, 2026, was $12.9 million, with cash and cash equivalents totaling $22.3 million at period end.
  • Average revenue per top 20 pharmaceutical manufacturer declined to $2,504 in the rolling twelve months ended September 30, 2026, from $3,087 in the prior year.
  • Net revenue retention decreased to 83% for the period ended September 30, 2026, compared to 121% in the prior year.
  • CEO Stephen L. Silvestro cited margin expansion & cost management as key drivers for the 23% increase in adjusted EBITDA despite revenue declines.
  • The company highlighted growth in contracted revenue for 2027 & renewed customer spending as indicators of future demand.
  • OptimizeRx continues to leverage its AI-enabled platform, proprietary healthcare data, & integrated EHR network as core competitive advantages.
  • Partnerships with DeepIntent, The Trade Desk, & PulsePoint are being utilized to broaden programmatic access to the company's network.
Company
OptimizeRx Corporation
Keywords
Nasdaq:OPRX, OptimizeRx Corporation